Hims Pricing Analysis and Total Cost: What You Actually Pay in 2026

How Hims Subscription Pricing Works

Hims operates a direct-to-consumer telehealth model where the consultation fee is folded into the monthly subscription price. You pay one bundled rate that covers an asynchronous provider visit, the medication itself, and standard shipping. There is no separate "platform fee" line item.

The catch is in billing cadence. Hims advertises its lowest per-month figure prominently, but that price typically requires committing to an annual plan paid upfront or in quarterly installments. A month-to-month subscriber paying for generic sildenafil 20 mg (as-needed dosing, 8 tablets) may pay $55 per month, while the same product drops to roughly $30 per month on an annual commitment. This 40 to 45% spread between monthly and annual pricing is consistent across most Hims product lines. A 2023 JAMA Network Open analysis of 38 D2C telehealth platforms found that subscription lock-in and opaque pricing were common across the sector, with only 42% of platforms disclosing total annualized cost on their landing pages [1]. Hims does display annual totals at checkout, but not on the initial product listing.

Shipping is free on standard delivery (5 to 7 business days). Expedited shipping adds $5 to $12 per order. Refills auto-ship unless paused or canceled through the Hims dashboard at least 48 hours before the next billing cycle.

Erectile Dysfunction: Cost Per Pill Breakdown

ED medications represent the highest-volume product line for Hims. Generic sildenafil (the active ingredient in Viagra) and generic tadalafil (the active ingredient in Cialis) are both available, along with compounded combination formulations.

For generic sildenafil 20 mg tablets prescribed as-needed, the per-pill cost on Hims ranges from $2.50 to $6.88 depending on quantity and plan length. GoodRx reports a retail cash price for generic sildenafil 20 mg of $0.40 to $3.00 per tablet at brick-and-mortar pharmacies [2]. That means Hims pricing is competitive with retail only at the annual-plan tier. Month-to-month Hims subscribers pay a premium for the bundled telehealth access and convenience.

Generic tadalafil 5 mg (daily dosing) runs $30 to $65 per month on Hims. The same 30-tablet supply at a retail pharmacy with a GoodRx coupon averages $9 to $25, though this requires a separate prescriber visit costing $50 to $250 out of pocket [2]. When you factor in a $75 average telehealth consultation fee from an independent provider, the Hims annual plan becomes roughly cost-neutral with the retail pharmacy route for tadalafil.

Hims also offers compounded "hard mints" (sildenafil-tadalafil sublingual troches) at $55 to $85 per month. Compounded formulations are not FDA-approved as combination products, a point the Endocrine Society has flagged in broader guidance on compounded hormonal therapies [3]. Patients should understand they are paying more for a formulation that has not undergone the same regulatory review as its individual generic components.

Hair Loss Products: Finasteride and Minoxidil Pricing

Oral finasteride 1 mg (generic Propecia) costs $25 to $30 per month through Hims. Retail pharmacy pricing for the same 30-tablet supply sits at $8 to $15 with discount coupons [2]. The Hims price premium here is 65 to 100%, attributable to the bundled consultation.

The topical finasteride-minoxidil spray, a compounded product, runs $35 to $55 per month. This formulation combines 0.1% finasteride with 6% minoxidil. A randomized controlled trial published in the Journal of the American Academy of Dermatology (N=458) found that topical finasteride 0.25% was non-inferior to oral finasteride 1 mg for androgenetic alopecia at 24 weeks, with lower systemic absorption of the drug [4]. The lower-concentration Hims formulation (0.1%) has not been independently studied at that specific dose in a large trial, which is worth noting.

Minoxidil alone (topical 5% solution) is available on Hims for $15 to $25 per month. The same product is sold over the counter at most pharmacies for $8 to $20 per month. This is one category where Hims offers minimal cost advantage or convenience benefit, since no prescription is required for minoxidil.

GLP-1 and Weight Management: What Hims Charges for Compounded Semaglutide

Hims entered the GLP-1 space by offering compounded semaglutide during the FDA-declared shortage period. Pricing ranged from $149 to $199 per month for subcutaneous injection kits, significantly below the $1,000+ monthly list price of brand-name Wegovy (semaglutide 2.4 mg, Novo Nordisk) [5].

The FDA shortage designation for semaglutide was resolved in February 2024, which raised legal questions about the continued compounding of semaglutide copies under Section 503A of the Federal Food, Drug, and Cosmetic Act [6]. Hims has publicly stated it continues to work within FDA guidance, but patients should verify current availability directly. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss at 68 weeks with branded semaglutide 2.4 mg versus 2.4% with placebo [7]. Compounded versions have not been tested in equivalent large-scale randomized trials, and dose accuracy from compounding pharmacies can vary.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Compounded GLP-1 medications are not interchangeable with FDA-approved products. Patients deserve to know that efficacy and safety data from clinical trials apply only to the branded formulation studied" [8].

For patients with insurance coverage for branded GLP-1 agonists, the out-of-pocket cost through a standard pharmacy benefit may be $25 to $150 per month with a manufacturer coupon or formulary coverage. Without insurance, Costco Pharmacy lists Wegovy at approximately $1,350 for a 4-week supply [5]. The Hims compounded option fills a real price gap, but with trade-offs in regulatory certainty and clinical evidence.

Men's Hormone Therapy and Testosterone Support

Hims markets a "testosterone support" supplement line ($30 to $45 per month) that includes DHEA, ashwagandha, and zinc. These are dietary supplements, not prescription testosterone. The distinction matters. A meta-analysis in Phytomedicine (12 RCTs, N=672) found that ashwagandha supplementation increased testosterone by a mean of 14.7% compared to placebo in men with low-normal levels, but absolute increases averaged only 17 ng/dL [9]. For men with clinically diagnosed hypogonadism (total testosterone consistently below 300 ng/dL per the American Urological Association threshold), supplement-grade interventions do not replace testosterone replacement therapy [10].

Hims does not currently prescribe injectable testosterone cypionate or topical testosterone gel through its platform in most states. Men seeking actual TRT will need to use a clinic-based telehealth provider or an in-person endocrinologist. This is a significant gap in the Hims product line relative to competitors like HealthRX, Defy Medical, or Peter Uncaged MD, where prescription TRT with lab monitoring is a core offering.

The AUA guidelines recommend baseline and follow-up labs (total testosterone, free testosterone, CBC, PSA, lipid panel, hepatic function) for any patient initiating TRT [10]. None of these labs are included in or ordered through the Hims supplement subscription.

Mental Health Medications: SSRIs and Anxiolytics

Hims prescribes generic SSRIs (sertraline, fluoxetine, paroxetine) and bupropion for depression and anxiety at $25 to $85 per month. Generic sertraline 50 mg (30 tablets) retails for $4 to $15 at most pharmacies with a discount card [2].

The mental health pricing on Hims is among the least competitive in its lineup. The primary value proposition is asynchronous prescriber access without an in-person visit. For patients who already have a primary care provider willing to prescribe SSRIs, Hims adds cost without clinical benefit. For patients without an established provider, the $25 to $30 per month entry tier may be reasonable as a combined consultation-plus-medication fee.

Hims mental health consultations are asynchronous (text-based questionnaire reviewed by a provider). A 2022 study in Psychiatric Services found that asynchronous telehealth visits for psychiatric medication management had comparable patient satisfaction scores to synchronous video visits (78% vs. 82%, P=0.11), though prescriber confidence in diagnostic accuracy was lower in the asynchronous group (64% vs. 79%, P<0.01) [11].

Hidden Costs and Fine Print

Several cost factors do not appear on the Hims product listing page:

Lab work. Hims does not operate its own lab network. When a provider determines that bloodwork is clinically necessary (common for hormone-related treatments and required before prescribing controlled substances in many states), patients must arrange and pay for labs independently. A basic hormone panel through Quest Diagnostics or Labcorp costs $75 to $200 out of pocket without insurance [12].

Refund policy. Hims processes refunds only within 14 days of the most recent shipment. After that window, cancellation stops future charges but does not refund the current billing period. Annual plans paid upfront are non-refundable after the 14-day window.

Pharmacy network. Hims uses affiliated pharmacies (including its own licensed pharmacy operations). Prescriptions cannot be transferred to an external pharmacy in most cases. This limits price-shopping. If a patient finds a cheaper source for the same generic medication, they cannot simply ask Hims to send the prescription elsewhere.

No insurance billing. Hims does not bill insurance. All payments are cash-pay. For medications with strong insurance formulary coverage (generic SSRIs, generic finasteride, generic sildenafil), this means Hims customers may pay substantially more than they would through their pharmacy benefit.

Hims vs. Alternative Telehealth Platforms: Price Comparison

Comparing Hims to three competitors across matched product categories:

ED (generic sildenafil, monthly): Hims $30 to $55. Ro (Roman) $25 to $52. BlueChew $20 to $90 (chewable format). HealthRX: pricing varies by provider consultation.

Hair loss (oral finasteride, monthly): Hims $25 to $30. Keeps $25. Ro $20 to $28.

GLP-1 (compounded semaglutide, monthly): Hims $149 to $199. Ro $149. Henry Meds $199 to $297.

Mental health (generic SSRI, monthly): Hims $25 to $85. Cerebral $30 to $85. Done $79 to $199.

Across these categories, Hims pricing clusters in the middle of the D2C telehealth market. It is rarely the cheapest option for any single product, but the breadth of its product catalog (ED, hair, skin, mental health, weight) creates convenience for patients who want a single platform.

The Endocrine Society's 2020 clinical practice guideline on testosterone therapy noted that "telehealth platforms providing hormonal therapies should ensure adequate laboratory monitoring and follow-up equivalent to in-person care" [3]. Patients comparing platforms should weight not just monthly price but also whether the platform includes lab ordering, result interpretation, and dose adjustment as part of the subscription.

Is Hims Legitimate?

Hims & Hers Health, Inc. (NYSE: HIMS) is a publicly traded company with a market capitalization exceeding $4 billion as of Q1 2026. It operates licensed pharmacies and contracts with state-licensed prescribers. The platform is legitimate in the regulatory sense: it is not a scam, and the medications dispensed are real pharmaceuticals from licensed facilities.

The BBB gives Hims an A- rating with approximately 2,100 customer complaints over the past three years, most related to billing disputes, auto-renewal charges, and difficulty canceling subscriptions [13]. The FTC has not taken enforcement action against Hims, though the broader D2C telehealth sector has faced increased scrutiny from state medical boards regarding asynchronous prescribing standards.

A 2024 JAMA Internal Medicine analysis of D2C telehealth prescribing patterns found that 71% of initial consultations on subscription platforms resulted in a prescription, compared to 52% for traditional telemedicine and 41% for in-person visits [14]. The authors noted that "the alignment of platform revenue with prescription volume creates structural incentives that may not always serve patient interests." Dr. Ateev Mehrotra, professor of health care policy at Harvard Medical School, commented: "These platforms work well for straightforward, guideline-concordant prescribing. The concern is when the business model pressures clinicians toward treatment in cases where watchful waiting might be more appropriate" [14].